Codonopsis

PreclinicalSmall molecule

ZZhejiang Provincial People's Hospital

Codonopsis is one of 5 small molecule programs targeting Adjuvant Chemotherapy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Adjuvant ChemotherapyUnknown status

Adjuvant ChemotherapyPreclinical

Unknown status

Competition

Competitive Landscape

4 competitors in Adjuvant Chemotherapy

#DrugCompanyPhaseTrials

FOLFOX

AstraZeneca

Phase 3

1 2

Adjuvant Chemotherapy

NNizhny Novgorod Regional Clinical Oncology Center

Phase 3

4 3

Tuoyi

SSun Yat-sen University

Phase 2

1 4

Capecitabine and Trastuzumab

FFudan University

Phase 2

1 5

Codonopsis

ZZhejiang Provincial People's Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Adjuvant Chemotherapy1 trial

Adjuvant Chemotherapy Plus Codonopsis Pilosula Nnannf /Placebo

Unknown status·ZZhejiang Provincial People's Hospital·N/A·NCT05613465·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Codonopsis. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Codonopsis compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Codonopsis. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zhejiang Provincial People's Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: ZZhejiang Provincial People's Hospital

Codonopsis

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Adjuvant Chemotherapy1 trial

References

Drug Info

Quick Facts

Related News